Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support 
Asian Markets Slide as Nvidia Earnings, U.S.-Iran Tensions and AI Valuations Weigh on Investor Sentiment 
Panama Investigates CK Hutchison’s Port Unit After Court Voids Canal Contracts 
FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
BlueScope Steel Shares Drop After Rejecting Revised A$15 Billion Takeover Bid 
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains 
BOJ Signals Possible April Rate Hike as Ueda Eyes Inflation and Wage Growth Data 
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules 
Global Markets Reel as Euro Falls, Swiss Franc Surges and Oil Prices Spike After U.S.-Israel Strike on Iran 
Toyota Plans $19 Billion Share Sale in Major Corporate Governance Reform Move 
Ecuador Raises Tariffs on Colombian Imports to 50% Amid Border Security Dispute 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
Dominican Republic Unveils Massive Rare Earth Deposits to Boost High-Tech and Energy Sectors 
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
